1. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Issue 2 (February 2020) Authors: Lonial, Sagar; Lee, Hans C; Badros, Ashraf; Trudel, Suzanne; Nooka, Ajay K; Chari, Ajai; Abdallah, Al-Ola; Callander, Natalie; Lendvai, Nikoletta; Sborov, Douglas; Suvannasankha, Attaya; Weisel, Katja; Karlin, Lionel; Libby, Edward; Arnulf, Bertrand; Facon, Thierry; Hulin, Cyrille; Kortüm, K Mart... Journal: Lancet oncology Issue: Volume 21:Issue 2(2020) Page Start: 207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗